Collaboration for the Clinical Implementation of Genomic Medicine for Inherited Retinal Degenerative Diseases
First written in FY2020. 4 of 6 entries say "Advanced", first in FY2022-Q2. Latest entry: FY2024-Q2.
No other company in this theme has enough history to compare yet.
- FY2024-Q2AdvancedAnnual report
「August 2023: The PrismGuide™ IRD Panel System, which provides information useful for identifying the causative genes of IRD by obtaining a comprehensive genomic profile from the blood of patients with or suspected of having inherited retinal dystrophy (IRD), and which received domestic manufacturing and marketing approval in May 2023, became the first IRD genetic panel testing system in Japan to receive reimbursement coverage.」
For IRD genomic medicine developed through collaboration with Kobe City Eye Hospital and others, the PrismGuide™ IRD Panel System became the first such system in Japan to receive coverage under the national health insurance system. - FY2024-Q1AdvancedAnnual report
「In the life sciences field, PrismGuide™ IRD Panel System, which obtains information on disease-causing genes for inherited retinal dystrophy (IRD), obtained Japan’s first manufacturing and marketing approval as a gene panel testing system for IRD. The system obtains a comprehensive genomic profile from blood samples of patients with IRD or suspected IRD, with the aim of identifying 82 disease-causing genes associated with IRD.」
For inherited retinal dystrophy, the jointly developed gene panel testing system obtained Japan’s first manufacturing and marketing approval and was realized as a clinical test covering 82 disease-causing genes. - FY2023-Q1AdvancedAnnual report
「In June 2022, the Company submitted an application for manufacturing and marketing approval for a gene panel testing system that detects and analyzes multiple genetic variant data for relevant genes from blood samples of patients with inherited retinal dystrophy, using next-generation sequencing, and supports the development of treatment plans and low-vision care plans according to the causative gene, as well as evidence-based genetic counseling.」
The gene panel testing system for inherited retinal dystrophy progressed from approval as Advanced Medical Care B and the policy of launching testing to the submission of an application for manufacturing and marketing approval in June 2022. - FY2022-Q3RestatedAnnual report
「In September 2021, genetic diagnosis and genetic counseling for inherited retinal dystrophy using the jointly developed IRD Panel Test System (tentative name) were approved as Advanced Medical Care B by Kobe City Eye Hospital, Kobe City Hospital Organization, and the Company.」
The approval as Advanced Medical Care B for genetic diagnosis and genetic counseling for inherited retinal dystrophy has been reposted as an achievement. - FY2022-Q2AdvancedAnnual report
「In addition, genetic diagnosis and genetic counseling for inherited retinal dystrophy using the gene panel test IRD Panel Test System (tentative name), which the Company has been jointly developing with Kobe City Eye Hospital, Kobe City Hospital Organization, was approved as Advanced Medical Care B. The Company will begin offering the test at Kobe City Eye Hospital and will increase the number of cooperating advanced medical care facilities able to perform the test to expand patients’ access to care.」
Genetic diagnosis and genetic counseling for inherited retinal dystrophy were approved as Advanced Medical Care B, progressing to a policy of launching the service at Kobe City Eye Hospital and expanding cooperating facilities. - FY2020First statedAnnual report
「In February 2020, the Company and Kobe City Eye Hospital, Kobe City Hospital Organization, entered into a comprehensive collaboration agreement on the clinical implementation of genomic medicine for inherited retinal degeneration.」
Through the comprehensive collaboration agreement with Kobe City Eye Hospital, the Company launched an initiative aimed at the clinical implementation of genomic medicine for inherited retinal degeneration.